eLearning Program

New Recommendations Reconfirm Bronchodilators as Cornerstone of COPD Treatment

Dr. Charles K.N. Chan — Length: 26:33

Chronic obstructive pulmonary disease (COPD) is a disease that is typically progressive, and not fully reversible, with chronic and continuous respiratory symptoms. The GOLD guidelines recommend LAMAs, LABAs and their combination as the cornerstone of therapy for GOLD B, C and D patients. Many LABA/LAMA combinations have been studied in COPD; however, not all of them have demonstrated the same benefits. This program will review the recommendations for dual therapy and the evidence supporting these recommendations.

eLearning Program

More than just Red Blood cells, Polycythaemia Vera is a Cancer

Dr. Nicholas Finn — Length: 26:35

Polycythaemia vera (PV) is a myeloproliferative neoplasm (MPN), a type of progressive blood cancer. Patients diagnosed with PV have a characteristic over-proliferation of not only red blood cells, but also of white blood cells and platelets. The symptoms of PV are driven by a number of underlying mechanisms. Therapy to adequately control these mechanisms is key to relieving PV patients from their burdensome symptoms and disease-related complications. Therapies are available to manage blood counts and minimize the risk of complications, even in patients who are intolerant or resistant to conventional therapies. This program will review PV, its diagnosis and available treatment options.

eLearning Program

Triple Therapy in COPD: Who and Why?

Dr. Shawn Aaron — Length: 26:39

Chronic obstructive pulmonary disease (COPD) is a disease that is typically progressive, and not fully reversible, with chronic and continuous respiratory symptoms. COPD is responsible for approximately 3 million deaths annually. The GOLD guidelines recommend a LAMA + LABA combination as initial therapy in patients with advanced disease (i.e., a predicted FEV1 of <30%). Triple therapy – a LAMA + LABA + an inhaled corticosteroid (ICS) – is recommended in patients who experience further exacerbation(s) on a LAMA + LABA combination. This program will review the recommendations for triple therapy and the evidence supporting these recommendations.

eLearning Program

Refractory Multiple Myeloma: The Shifting Treatment Paradigm

Dr. Donna E. Reece — Length: 23:32

There has been a recent and important expansion in the treatment options for relapsed and refractory multiple myeloma. These options, which included new drugs from existing therapeutic classes and novel agents that have introduced unique mechanisms of action, provide an opportunity to extend disease control with a good quality of life. In this program, new treatment options for advanced multiple myeloma are explored with attention to the rationale for individualizing treatments to prolong survival.

eLearning Program

Familial Hypercholesterolemia: Preventing Cardiovascular Events

Dr. Robert A. Hegele — Length: 34:37

Based on current estimates, more than 85,000 Canadians have familial hypercholesterolemia, most of whom remain undiagnosed. This condition dramatically accelerates the development of atherosclerosis, driving an accelerated rate of cardiovascular disease, including about an 8-fold increase in risk of cardiovascular death in individuals between the ages of 20 and 50 years. The introduction of PCSK9 inhibitors has provided an opportunity to normalize the lifespan of these individuals.

eLearning Program

Bile Acid Diarrhea (BAD): Treatable But Under Recognized

Dr. Alan Barkun — Length: 08:43

Bile acid diarrhea (BAD) is an easily overlooked cause of chronic diarrhea. It is particularly common in patients for whom other causes of chronic diarrhea cannot be identified, including those given a diagnosis of the diarrhea variant of irritable bowel syndrome (IBS-D). Confirmed objectively with fecal stool tests or more sophisticated radiolabelling studies, BAD may also be diagnosed with a trial of a bile acid sequestrant. By controlling symptoms, bile acid sequestrants can establish the diagnosis and treat the underlying disorder.

eLearning Program

Standard of Care Revisited: Optimizing Glycemic Control in Type 2 Diabetes Mellitus

Dr. Tina Kader — Length: 22:55

Type 2 diabetes mellitus (T2DM) is a progressive disorder that typically requires incremental intensification of therapy over time to maintain target glycemic control. Uncomplicated regimens are essential. Patients with T2DM typically require multiple agents to control associated cardiovascular risk factors on top of therapy to lower blood glucose. The value of a once-daily formulation of metformin, which is recognized as the cornerstone of antidiabetic therapy because it is effective, well tolerated, and cardioprotective, is its ability to simplify therapy. In this program, the strategies for early and sustained control of T2DM are evaluated in the context of once-daily metformin and other well-tolerated therapies that permit simple dosing and a low risk of counterproductive side effects, such as weight gain.

This web site is solely for healthcare professionals

Yes, I am a healthcare professional No, I am not a healthcare professional